Variability in Global Drug Prices

US brand-name drug prices are 2-4 times higher than in other industrialized countries because the US lacks the comparative effectiveness assessments and government price negotiations used elsewhere. The Inflation Reduction Act’s limited Medicare negotiation authority and generic/biosimilar competition represent the most promising approaches to reducing costs.